CoChat

Oral birch pollen immunotherapy with apples: Results of a phase II clinical pilot study

Open access
Nothegger, Bettina, Reider, Norbert, Covaciu, Claudia E., Cova, Valentina, Ahammer, Linda, Eidelpes, Reiner, Unterhauser, Jana, Platzgummer, Stefan, Raffeiner, Elisabeth, Tollinger, Martin, Letschka, Thomas, Eisendle, Klaus · 2021 · Immunity, Inflammation and Disease
Cited by 21

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Background: Seventy percent of patients suffering from birch pollen allergy (BPA) develop a pollen‐related food allergy (prFA), especially to apples, due to a clinically relevant cross‐reactivity between the major allergen in birch Bet v 1 and Mal d 1 in apples. Therefore allergen‐specific immunotherapy with fresh apples (AITA) could be a promising natural treatment of both BPA and prFA. Objective: To assess the clinical efficacy of immunotherapy by daily apple consumption for patients with BPA and prFA. Methods: A daily defined increasing amount of selected cultivars (Red Moon®, Pink Lady®, Topaz, Golden Delicious) was continuously consumed by 16 patients (12 female; median age; 50; range, 23–68 years), leading to increased intake of allergen over a period of at least 8 months. Specific IgE and IgG 4 to Bet v 1 and Mal d 1, conjunctival and oral provocation tests, skin reactivity, and the average daily rhinoconjunctivitis combined symptom and medication score (CSMS) were measured during the peak birch pollen season. Results: After 8 months of therapy, patients showed increased tolerance to apples (p < .001) and a decreased skin reactivity to apples. Oral allergy syndrome to other birch prFA than apple also decreased (p < .05). Moreover, daily rhinoconjunctivitis CSMS declined by 34% (p < .001), as did conjunctival reactivity to birch pollen extract by 27% (p < .01), while specific IgG 4 to Mal d 1 and Bet v 1 increased (p < .01).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/iid3.410

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 21

Metadata

Authors
Nothegger, B., Reider, N., Covaciu, C. E., Cova, V., Ahammer, L., Eidelpes, R., Unterhauser, J., Platzgummer, S., Raffeiner, E., Tollinger, M., Letschka, T., & Eisendle, K.
Venue
Immunity, Inflammation and Disease
Publisher
Wiley
Published
2021-02-23
Volume
9
Issue
2
Pages
503-511
ISSN
2050-4527 (ISSN-L)
OpenAlex
W3129746737
Cited by
21
References
1
FWCI
2.21
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Oral birch pollen immunotherapy with apples: Results of a phase II clinical pilot study. https://app.cochat.ai/papers/10.1002/iid3.410
The paper
Nothegger, B., Reider, N., Covaciu, C. E., Cova, V., Ahammer, L., Eidelpes, R., Unterhauser, J., Platzgummer, S., Raffeiner, E., Tollinger, M., Letschka, T., & Eisendle, K. (2021). Oral birch pollen immunotherapy with apples: Results of a phase II clinical pilot study. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.410

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.